Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)

This study is testing a stem cell-based treatment for Parkinson's disease, where lab-grown dopamine-producing cells (made from iPS cells, a type of reprogrammed stem cell) are transplanted into the brain to replace the cells lost in Parkinson's. This is a Phase I/II safety and early efficacy trial. **You may be eligible if...** - You are 40–75 years old - You have had a confirmed Parkinson's disease diagnosis for at least 5 years - Your symptoms fluctuate between "ON" times (when medication is working) and "OFF" times (when it isn't) - Your medications are no longer providing adequate control - You respond to levodopa (a standard Parkinson's drug) by at least 30% - Your disease is at a moderate stage (Hoehn and Yahr stage 2 or higher when "off") **You may NOT be eligible if...** - You have severe uncontrolled movement complications (dyskinesia) - You have dementia or significant cognitive decline - You have had deep brain stimulation surgery - You have a history of brain cancer or significant brain abnormalities Talk to your doctor to see if this trial is right for you.